CTD² researchers at the Broad Institute/DFCI have developed a collection of plasmids including mutant alleles found in sequencing studies of cancer. It includes somatic variants found in lung adenocarcinoma and across other cancer types. The clones enable researchers to characterize the function of the cancer variants in a high throughput experiments. These plasmids are collectively called the... Read More
To accelerate the cancer target discovery, CTD² aims to disseminate knowledge, data, tools and resources with the scientific community. This page provides a list of materials (including plasmids, cell lines, cell models, etc.) which are generated by CTD²-supported research and are available for use by researchers. Each reagent listed is accompanied by a short description; more detailed information can be obtained from the generating laboratory (contact information provided). Some reagents are available through a distributor, while others are available directly from the generating laboratory. Many of these reagents require material transfer agreements (MTAs) for use. The requestor should work directly with the generating institution to complete the MTA. OCG will not be responsible for obtaining the MTA but will provide information for contacting the generating laboratory.
The CTD² Center at UT-MD Anderson Cancer Center has developed a High-Throughput Mutagenesis and Molecular Barcoding (HiTMMoB)1,2 pipeline to construct mutant alleles open reading frame expression clones that are either recurrent or rare in cancers. These barcoded genes can be used for context-specific functional validation, detection of novel biomarkers (pathway activation) and... Read More
CTD² researchers at the University of California in San Francisco developed a modified Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) CRISPR/dCas9 system. Catalytically inactive dCas9 enables modular and programmable RNA-guided genome regulation in eukaryotes. The CRISPR/dCas9 system has several advantages: i) enables robust gene... Read More
A large number of gene mutations give proteins new capabilities to bind cellular proteins and create new signaling pathways that drive tumor growth. To discover and validate mutation-created protein-protein interactions (PPI) as therapeutic targets for cancer, the CTD² Center at Emory University has created PPI expression vector libraries. A list of available cancer-associated genes can be... Read More